Loading
A phase 1 trial of MT-601 run by Marker Therapeutics, Inc., not yet recruiting.
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer is a phase 1 interventional study registered as NCT06549751 by Marker Therapeutics, Inc., with 38 participants planned, started 2026-07-16. Conditions recorded: Pancreas Cancer, Pancreatic Cancer Metastatic and Pancreatic Cancer (Unresectable). Interventions recorded: MT-601 dose 200 million cells, MT-601 dose 400 million cells, MT-601 dose 800 million cells and MT-601 dose 1200 million cells.
Shares Marker Therapeutics, MT-601 and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/